| Original language | English (US) |
|---|---|
| Pages (from-to) | 1009-1011 |
| Number of pages | 3 |
| Journal | Journal of Cardiac Failure |
| Volume | 25 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2019 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure : HFpEF Eligibility for PARAGON-HF. / Sayeed, Sabina; Fudim, Marat; Devore, Adam D.; Xu, Haolin; Matsouaka, Roland A.; Heidenreich, Paul A.; Yancy, Clyde W.; Fonarow, Gregg C.; Hernandez, Adrian F.
In: Journal of Cardiac Failure, Vol. 25, No. 12, 12.2019, p. 1009-1011.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure
T2 - HFpEF Eligibility for PARAGON-HF
AU - Sayeed, Sabina
AU - Fudim, Marat
AU - Devore, Adam D.
AU - Xu, Haolin
AU - Matsouaka, Roland A.
AU - Heidenreich, Paul A.
AU - Yancy, Clyde W.
AU - Fonarow, Gregg C.
AU - Hernandez, Adrian F.
N1 - Funding Information: M. Fudim consults for Coridea, AxonTherapies, and Galvani; A.D. DeVore, company relationships: Akros Medical, AstraZeneca, Amgen, American Heart Association, Bayer, Luitpold Pharmaceuticals, NHLBI, PCORI, Novartis; consultant: AstraZeneca, Mardil Medical, Novartis, Procyrion; G.C. Fonarow, company relationship: NIH; consultant: Abbott, Amgen, Bayer, Janssen, Medtronic, Novartis; A.F. Hernandez: company relationships: AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Luitpold Pharmaceuticals, Merck, Novartis, Honoraria, Bayer, Boston Scientific, Novartis. All other authors have no relevant disclosures. The Get With The Guidelines®-Heart Failure (GWTG-HF) program is provided by the American Heart Association. GWTG-HF is sponsored, in part, by Amgen Cardiovascular and has been funded in the past through support from Medtronic, GlaxoSmithKline, Ortho-McNeil, and the American Heart Association Pharmaceutical Roundtable. Powered by IQVIA, Cambridge, MA. Duke Clinical Research Institute (DCRI) served as the data analysis center. Funding Information: Funding: M. Fudim is supported by an American Heart Association Grant 17MCPRP33460225 and NIH T32 Grant 5T32HL007101.
PY - 2019/12
Y1 - 2019/12
UR - http://www.scopus.com/inward/record.url?scp=85075939914&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075939914&partnerID=8YFLogxK
U2 - 10.1016/j.cardfail.2019.10.003
DO - 10.1016/j.cardfail.2019.10.003
M3 - Letter
C2 - 31626949
AN - SCOPUS:85075939914
VL - 25
SP - 1009
EP - 1011
JO - Journal of Cardiac Failure
JF - Journal of Cardiac Failure
SN - 1071-9164
IS - 12
ER -